A LC-MS-MS assay for simultaneous determination of two glycopeptides and two small molecule compounds in human plasma
A LC-MS-MS assay for simultaneous determination of two glycopeptides and two small molecule compounds in human plasma
复制标题
LC→MS-MS 测定同时测定人血浆中的两种糖肽和两种小分子化合物
DOI:
10.1093/chromsci/bmy060
复制
发表时间:
2018-10-01
影响因子:
1.3
通讯作者:
Li, Yanyan
中科院分区:
文献类型:
--
作者:
Shi, Meiyun;Zhao, Xiaojun;Li, Yanyan
In this study, a novel and high-throughput liquid chromatography-tandem mass spectrometric (LC-MS-MS) assay was developed and validated for simultaneous determination of two glycopeptides (vancomycin, teicoplanin) and two small molecule compounds (meropenem, voriconazole) in human plasma. Only 50 mu L of human plasma is used to quantify these four drugs simultaneously at clinical concentration levels. After a relative simple protein precipitation, the supernatant was then diluted with mobile phase acetonitrile: 0.1% formic acid (5:95, v/v) to avoid solvent effect and reduce the matrix effect. Then, the target compounds were separated on an Agilent Zorbax SB-C18 column (4.6 x 50 mm, 2.7 mu m). All the target compounds were detected by positive ion mode. The teicoplanin concentration was determined as the sum of six components (A2-1, A2-2, A2-3, A2-4, A2-5 and A3-1). The method was linear in the concentration range 0.3-30 mu g/mL for meropenem; 1-100 mu g/mL for teicoplanin and vancomycin; 0.3-10 mu g/mL for voriconazole. The lower limit of quantitation (LLOQ) of meropenem and voriconazole were 0.30 mu g/mL; and the LLOQ of teicoplanin and vancomycin were 1.0 mu g/mL. The intra- and inter-day accuracies were